Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12317853 | 0.90 | ROCK2 (0.43) | MAPK1MAPK3AKT1ITKGSK3B | |
| SCHEMBL12269784 | 0.84 | AKT1 (0.40) | MAPK1MAPK3AKT1S1PR3S1PR1 | |
| SCHEMBL12317927 | 0.76 | MAP2K4 (0.48) | MAPK1MAP2K4ITK | |
| SCHEMBL12317929 | 0.75 | MAP2K4 (0.53) | MAPK1MAP2K4ITKDYRK1A | |
| SCHEMBL12269673 | 0.74 | ROCK2 (0.39) | MAPK1AKT1S1PR3GSK3BDYRK1A | |
| SCHEMBL12317932 | 0.72 | ITK (0.53) | MAPK1MAPK3ITK | |
| SCHEMBL12318101 | 0.72 | ITK (0.51) | MAPK1MAPK3ITK | |
| SCHEMBL12653398 | 0.72 | L3MBTL1 (0.41) | MAPK1MAPK3ITKGSK3BDYRK1A | |
| SCHEMBL12317931 | 0.72 | GSK3B (0.47) | ITKGSK3BDYRK1A | |
| SCHEMBL12317933 | 0.70 | ATM (0.52) | ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2011-09-01 | — | — | US | disclosed |
| US-7951832-B2 | Pyrazole derivatives as kinase inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BRAF, MAP3K1, MAP3K3 | MAPK1 81/4885MAPK3 31/4885AKT1 88/4885 |
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BRAF, MAP3K1, MAP3K3 | MAPK1 81/4885MAPK3 31/4885AKT1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.